Biotech News

Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update

Alvotech (ALVO)AlvotechEarnings

Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the nine months to September 30, 2026, and provided a business update.

Related news

Alvotech

Global Biosimilar Developer and Manufacturer Alvotech is a biotechnology company focused exclusively on developing and manufacturing biosimilar medicines. It operates an integrated model covering cell-line development, process development, clinical studies, regulatory submissions, commercial-scale manufacturing, and supply to regional...

Recent company news

Stock data

Close
4.29 USD
Market cap
936.14M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States